-+ 0.00%
-+ 0.00%
-+ 0.00%

RECURSION PHARMACEUTICALS - PHASE 2 SHOWS 47% MEDIAN POLYP BURDEN REDUCTION, 85% EVALUABLE PATIENTS BELOW BASELINE AFTER 12 WEEKS OFF-TREATMENT

Reuters·11/02/2026 21:25:09

Please log in to view news